

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

<i>Complete if Known</i>	
<i>Application Number</i>	10/660,131
<i>Filing Date</i>	September 11, 2003
<i>First Named Inventor</i>	David H. Munn et al.
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Regina M. DeBerry
<i>Attorney Docket Number</i>	M0351-287806

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

<i>Application Number</i>	10/660,131
<i>Filing Date</i>	September 11, 2003
<i>First Named Inventor</i>	David H. Munn et al.
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Regina M. DeBerry
<i>Attorney Docket Number</i>	M0351-287806

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	BABAN et al., "A Minor Population of Splenic Dendritic Cells Expressing CD19 Mediates IDO-Dependent T Cell Suppression Via Type 1 IFN Signaling Following 87 Ligation," <i>International Immunology</i> , 2005, 17(7): 909-919	
	7	BJORCK et al., "Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice" <i>Blood</i> , 2001, 98(13): 3520-3526.	
	8	BORRAS et al., "Identification of Both Myeloid CD11c and Lymphoid CD11c Dendritic Cell Subsets in Cord Blood." <i>British Journal of Haematology</i> , 2001, 113: 925-931.	
	9	CADY et al., "1-Methyl-DL-tryptophan, beta-(3benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase," <i>Archives of Biochemistry and Biophysics</i> , 1991, 291(2): 326-333 (Abstract)	
	10.	CHAPMAN et al., "Pharmacologically active benzo[b]thiophene derivatives. VIII Benzo[b]thiophene analogs of tryptophan and alpha,-methyltryptophan, and some of their 5-substituted derivatives," <i>Journal of the Chemical Society, Section C: Organic Chemistry</i> , 1969, No. 14: 1855-1858 (Abstract).	
	11	DAGHER et al., "Pilot Trial of Tumor-Specific Peptide Vaccination and Continuous Infusion Interleukin-2 in Patients with Recurrent Ewing Sarcoma and Alveolar Rhabdomyosarcoma: An Inter-Institute NIH Study," <i>Med. Pediatr. Oncol.</i> , 2002, 38: 158-164	
	12	European Patent Office, Supplementary Partial European Search Report, Application No. EP 02 80 7233, Date of Completion of the Search October 19, 2005. 5 pages.	
	13	FRIBERG et al., "Indoleamine 2,3-Dioxygenase Contributes to Tumor Cell Evasion of T Cell-Mediated Rejection," <i>Int. J. Cancer</i> , 2002, 101: 151-155.	
	14	FRIBERG et al., "Indoleamine 2,3-dioxygenase (IDO) protects established tumors from T cell mediated rejection," <i>Proc. Amer. Ass. Cancer Res. Ann. Meet.</i> , 2000, No. 714, page 112 (Abstract).	
	15	FRUMENTO et al., "Inhibition of T cell proliferation by the purified enzyme indoleamine 2,3-dioxygenase," <i>Human Immunology, The European Federation for Immunogenetics 14th Annual Conference, April 4-7, 2000</i> , 61: page S140 (Abstract)	
	16	GROHMANN et al., "IFN- γ Inhibits Presentation of a Tumor-Self Peptide by CD8a- Dendritic Cells Via Potentiation of the CD8a+ subset" <i>Journal of Immunology</i> , 2000, 165(3): 1357-1363.	
	17	HWU et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation" <i>J. Immunol.</i> , 2000, 164: 3596-3599.	
	18	International Search Report for PCT/US02/11319, filed April 12, 2002 mailed September 6, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

<i>Application Number</i>	10/660,131
<i>Filing Date</i>	September 11, 2003
<i>First Named Inventor</i>	David H. Munn et al.
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Regina M. DeBerry
<i>Attorney Docket Number</i>	M0351-287806

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	LEE et al., "Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma," <i>Laboratory Investigation</i> , 2003, <u>83</u> (10): 1457-1466.	
	20	MELLOR et al., "Extinguishing Maternal Immune Responses during Pregnancy: Implications for Immunosuppression," <i>Seminars in Immunology</i> , 2001, <u>13</u> (4): 213-218.	
	21	MELLOR et al., "Tryptophan catabolism and T cell tolerance: immunosuppression by starvation?" <i>Immunology Today</i> , 1999, <u>20</u> : 469-473.	
	22	MELLOR et al., "Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses," <i>J. Reprod. Immunol.</i> , 2001, <u>52</u> (1-2): 5-13.	
	23	MELLOR et al., "HLA-G transgenic mice," <i>J. Reprod. Immunol.</i> , 1999, <u>43</u> : 253-261.	
	24	MELLOR et al., "Immunology at the maternal-fetal interface," <i>Ann. Rev. Immunol.</i> , 2000, <u>18</u> : 367-391.	
	25	MELLOR et al., "IDO expression by dendritic cells: tolerance and tryptophan catabolism" <i>Nat. Immunol. Rev.</i> , 2004, <u>4</u> : 762-774.	
	26	MUNN et al., "Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells," <i>Journal of Immunology</i> , 2004, <u>172</u> : 4100-4110.	
	27	MUNN et al., "Dendritic Cells Have the Option to Express IDO-Mediated Suppression or Not," <i>Blood</i> , 2005, <u>105</u> (6): 2618.	
	28	MUNN et al., "Macrophage inhibition of T cell activation via depletion of tryptophan," <i>Blood</i> , 1998, <u>48</u> -IV, (Abstract).	
	29	MUNN et al., "Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase," <i>Science</i> , 2002, <u>297</u> : 1867-1870.	
	30	MUNN et al., "Regulation of T cell activation by macrophage (Mvariant phi)-mediated tryptophan (TRP) depletion," <i>FASEB Journal</i> , 1998, <u>12</u> : page A276 (Abstract).	
	31	MUNN et al., "Tolerogenic Antigen-Presenting Cells," <i>Ann. NY. Acad. Sci.</i> , 2002 <u>961</u> : 343-345.	
	32	OSUGI et al., "Myeloid Blood CD11c+ Dendritic Cells and Monocyte-Derived Dendritic Cells Differ in their Ability to Stimulate T Lymphocytes," <i>Blood</i> , 2002, <u>100</u> (8): 2858-2866.	
	33	PACANOWSKI et al., "Reduced blood CD123 ⁺ (lymphoid) and CD11c ⁺ (myeloid) dendritic cell numbers in primary HIV-1 infection" <i>Blood</i> , 2001, <u>98</u> (10): 3016-3021.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

<i>Application Number</i>	10/660,131
<i>Filing Date</i>	September 11, 2003
<i>First Named Inventor</i>	David H. Munn et al.
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Regina M. DeBerry
<i>Attorney Docket Number</i>	M0351-287806

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	PETERSON et al., "Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase." <i>Medicinal Chemistry Research</i> , 1994, <u>3</u> (8): 531-544 (Abstract).	
	35	POTULA et al., "Inhibition of Indoleamine 2,3-Dioxygenase (IDO) Enhances Elimination of Virus-Infected Macrophages in an Animal Model of HIV-1 Encephalitis," <i>Blood</i> , 2005, <u>106</u> (7): 2382-2390	
	36	REDDY et al., "A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells" <i>Blood</i> , 1997, <u>90</u> (9): 3640-3646.	
	37	ROMANI et al., "Generation of mature dendritic cells from human blood" <i>Immunol. Meth.</i> , 1996, <u>196</u> : 137-151.	
	38	SOUTHAN et al., "Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase." <i>Medicinal Chemistry Research</i> , 1996, <u>6</u> (5): 343-352 (Abstract).	
	39	TAN et al., "Creation of Tolerogenic Human Dendritic Cells via Intracellular CTLA4: A Novel Strategy with Potential in Clinical Immunosuppression," <i>Blood</i> , 2005, <u>106</u> (9): 2936-2943.	
	40	TAN et al., "Modulation of human dendritic cell function following transduction with viral vectors; implications for gene therapy," <i>American Society of Hematology, Blood First Edition Paper</i> , prepublished online January 25, 2005.	
	41	TERNESS et al., "Regulation of Human Auto-and Alloreactive T Cells by Indoleamine 2,3-Dioxygenase (IDO)-Producing Dendritic Cells. Too Much Ado about IDO?" <i>Blood</i> , 2005, <u>105</u> (6): 2480-2486.	
	42	TERNESS et al., "The Immunoregulatory Role of IDO-Producing Dendritic Cells Revisited," <i>Trends in Immunology</i> , 2006, <u>27</u> : 68-73.	
	43	YOSHIDA et al., "Tryptophan Degradation in Transplanted Tumor Cells Undergoing Rejection." <i>Journal of Immunology</i> , 1988, <u>141</u> (8): 2819-2823.	
	44	Office Action mailed 08/13/2007 for U.S. Patent Application Serial No. 10/121,909.	
	45	Response to Non-Final Office Action sent to the USPTO on 05/15/2007 for U.S. Patent Application Serial No. 10/121,909.	
	46	Office Action mailed 11/16/2006 for U.S. Patent Application Serial No. 10/121,909.	
	47	Election and Response sent to the USPTO on 08/24/2006 for U.S. Patent Application Serial No. 10/121,909.	
	48	Office Action (Restriction) mailed 07/13/2006 for U.S. Patent Application Serial No. 10/121,909.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn et al.
Art Unit	1647
Examiner Name	Regina M. DeBerry

Attorney Docket Number

M0351-287806

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	49	Amendment and Response to Office Action Pursuant to 37 C.F.R. § 1.114 (with Request for Continued Examination) sent to the USPTO on 04/20/2006 for U.S. Patent Application Serial No. 10/121,909.	
	50	Advisory Action mailed 04/03/2006 for U.S. Patent Application Serial No. 10/121,909.	
	51	Amendment and Response to Office Action sent to the USPTO on 03/22/2006 U.S. Patent Application Serial No. 10/121,909.	
	52	Office Action mailed 12/22/2005 for U.S. Patent Application Serial No. 10/121,909.	
	53	Amendment and Response to Office Action sent to the USPTO on 09/28/2006 for U.S. Patent Application Serial No. 10/121,909	
	54	Office Action mailed 06/28/2005 for U.S. Patent Application Serial No. 10/121,909.	
	55	Election and Response sent to the USPTO on 04/18/2005 for U.S. Patent Application Serial No. 10/121,909.	
	56	Office Action (Restriction) mailed 03/17/2005 for U.S. Patent Application Serial No. 10/121,909.	
	57	Preliminary Amendment sent to the USPTO on 04/12/2002 for U.S. Patent Application Serial No. 10/121,909.	
	58	Australia: First Statement of Proposed Amendments sent to the Australian Patent Office on 11/12/2004 for Australian Patent Application No. 2002307243.	
	59	Australia: Examiner's First Report mailed 07/04/2007 for Australian Patent Application No. 2002307243.	
	60	Australia: Response to Examiner's First Report sent to the Australian Patent Office on 09/14/2007 for Australian Patent Application No. 2002307243.	
	61	Canada: Office Action mailed 05/09/2007 for Canadian Patent Application No. 2,483,451.	
	62	Canada: Response to Office Action sent to the Canadian Patent Office on 10/17/2007 for Canadian Patent Application No. 2,483,451	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Application Number</i>	10/660,131
		<i>Filing Date</i>	September 11, 2003
		<i>First Named Inventor</i>	David H. Munn et al.
		<i>Art Unit</i>	1647
		<i>Examiner Name</i>	Regina M. DeBerry
Sheet	6	of	6
		<i>Attorney Docket Number</i>	M0351-287806

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique claim designation number (optional). Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 end and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.